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Treatment : No clear consensus, but 
• Complete surgical resection when possible (partial recurrence) 
• If not, first-line drugs :  
Vincristine 0,05 mg/kg Once weekly (central line) AND 
oral Prednisolone 2 mg/kg/d or IV Methylprednisolone 1,6 mg/kg/d  
• Or SIROLIMUS (inhibitor of the mammalian target of rapamycin) 
Antiproliferative and antiangiogenetic agent. 
Improves rapidly the hematopoietic parameters. 
Acceptable side effects : hyperglycemia, hyperlipidemia, lymphopenia. 
• Others: 
 Propranolol (with corticosteroids, best in infantile hemangioma) 
 Interferon-α (toxicity!) 
 Antiplatelets agents (efficacity on inflammation and pain) 
 Embolization, rarely realizable 
 Radiation therapy, inefficient 
• RESTRICTED PLATELETS TRANSFUSION only for active bleeding   
or prior to surgery 
Short half-live owing to intraregional trapping and destruction. 
Exacerbates the KMP, increasing pain and enlargement of the tumor.  
Stimulates endothelial proliferation by release of pro-angiogenicGF.  
Prognosis : 
- High mortality rate (10-30%), correlated to haemorrhagic complications. 
- Residual lesions: pseudo-fibrosis, inflammatory surge or bone/muscle 








      CLINICAL CASE  
 
• Well-being male fetus, normal pregnancy. 
• Routine ultrasonography unspecific at 36 weeks of gestation. 
• At 38 weeks, discovery of a right voluminous cervicofacial mass. 










     The C-section delivery is quickly planed in the referral materno-fetal  
      intensive care unit center, involving a multidisciplinary team. 
 
At birth :  
The newborn breathes spontaneously but presents severe hypoxemia. 
The huge purple mass is firm and non-painful. A diffuse petechial rash is 
noted. 
 
Direct laryngoscopy shows a left shift of the upper airway tract and laryngeal 
structures invasion by the hemangioma. Active bleeding is at once 
significant. 
 
Laryngeal mask ventilation is performed until intubation under video-
laryngoscopic control can be succeeded. 
Umbilical venous catheter is placed to ensure hemodynamics and 
comfort. 
 












































KHE: firm infiltrative and solitary vascular tumor located in the skin  
or soft tissue, usually seen in infancy. 
KMP: coagulopathy complicating mainly the KHE. The intensity  
of thrombocytopenia seems related to the extent of tumor infiltration.  
Epidemiology : 
- Less than 1 birth per million. 
- No gender or ethnicity predominance. 
- Frequent in first weeks of life (prenatally diagnosis increase disease severity). 
- Preferantial location : lateral neck, axilla, groin, extremities, trunk. 
Physiopathology hypothesizes:  
Abnormal platelet activation and aggregation in contact to an abnormal tumor 
endothelium and/or turbulent blood flow in the small convoluted capillaries. 
    → localized trapping of platelets and consumption of clotting factors. 
 
 
CONCLUSION :  
A fast-growing vascular mass which is high located should always be feared. The delivery must be programmed in a materno-fetal intensive care unit center, 
where a multidisciplinary support can be proposed. An Exit procedure could also be evoked in an experimented unit. 
KASABACH-MERRITT is a life-threatening phenomenon characterized by severe thrombocytopenia and consumptive coagulopathy. It is a common complication 
of a rapidly enlarging rare vascular tumor known as kaposiform hemangioendothelioma (KHE).  
To this day, there is no consensus regarding the treatment but emerging drugs as Sirolimus seem to be efficient. Our experience corroborates with reported fast 
and spectacular effects on the platelets count and the mass size. Its oral administration and apparent safety profile are also attractive. 
Platelets transfusion should be avoided at best, considering the risk to worsen the situation and enlarge the mass. 
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Coronal T2-weighted-MR-images demonstrate a 
vascular mass, involving the parapharyngeal and retro-
pharyngeal spaces and the floor of the mouth. We note 
a lateral deviation of the oropharynx and the larynx with 
reduction of the respiratory tracts. 
Evolution :  
Immediate   
- Moderate anemia (Hb 10.4 g/dl), profound thrombocytopenia 
(11000/mm³) + coagulation disorders (fibrinogen 0,7 g/dl, D-Dimers 
level > 4000 µg/L) 
Diagnosis of  KASABACH-MERRIT phenomenon 
 
- Tritherapy start (Vincristine-Propranolol-Methylprednisolone) since day 1        
according to the severe life-threatening condition. 
- Platelets transfusions (when less than 20000/mm³) are given until day 8 of 
life because of heavy invasive support and expected drug delay efficiency. 




- Sirolimus introduction at day 8 of life.  
 Normalization of platelets count in 1 week and visible tumor 
involution. 
- Successful first extubation after fibroscopic control at the 5th week of life. 
- Continuation of Sirolimus for months. 
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Sirolimus  0.05 mg/kg/dose 2x/day 
Vincristine 1 mg/kg/m² 1x/week 
Platelets 
transfusions  
Propranolol   2 mg/kg/day 































Tranexamic acid 15 mg/kg/day 
 
Ticlopidine 10 mg/kg/day 
